Fluvoxamine-Voriconazole-Bupropion-DDI

Modeling of published clinical Fluvoxamine-Voriconazole-Bupropion DDI study for model evaluation

Repository files

Within this repository, we distribute a PK-Sim project file containing simulations of a published clinical study used to evaluate the predictive performance of the bupropion model regarding the fluvoxamine-voriconazole-bupropion-DDI, including the respective observed data digitized from literature reports. The applied fluvoxamine and voriconazole models have been published previously [1,2]. For further details and documentation please refer to [3].

Version information

PK-Sim Version 9.1.

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model is distributed under the GPLv2 Lincense.

Reference

[1] Britz H, Hanke N. Volz A, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. Physiologically-based pharmacokinetic models for CYP1A2 drug–drug interaction prediction: A modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam. CPT Pharmacomet. Syst. Pharmacol. 2019; 8, 296–307

[2] Li X, Frechen S, Moj D, Lehr T, Taubert M, Hsin C-H, Mikus G, Neuvonen PJ, Olkkola KT, Saari TI, Fuhr U. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug–Drug Interactions. Clin. Pharmacokinet. 2020; 59, 781–808

[2] Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network. Pharmaceutics. 2021; 13(3),331